Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria

OBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine. METHODS: Nineteen males and 13 females aged between 14 and 60 years with confirmed diagnosis of PNH wer...

Full description

Bibliographic Details
Published in:Turkish Journal of Hematology
Main Authors: Kanjaksha Ghosh, Manisha Madkaikar, Maya Gupta, Farah Jijina
Format: Article
Language:English
Published: Turkish Society of Hematology 2013-12-01
Subjects:
Online Access:https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-80664
_version_ 1848651635730939904
author Kanjaksha Ghosh
Manisha Madkaikar
Maya Gupta
Farah Jijina
author_facet Kanjaksha Ghosh
Manisha Madkaikar
Maya Gupta
Farah Jijina
author_sort Kanjaksha Ghosh
collection DOAJ
container_title Turkish Journal of Hematology
description OBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine. METHODS: Nineteen males and 13 females aged between 14 and 60 years with confirmed diagnosis of PNH were treated with danazol (4), danazol + cyclosporine (7), cyclosporine (1), and prednisolone + danazol (20). Response to these interventions was assessed regularly. Danazol was added to cyclosporine in patients with aplastic bone marrow after 3 months of cyclocporine use only unless the former therapy was successful. Four patients with aplastic marrow received only danazol because they had renal insufficiency at presentation. Patients were evaluated with regular complete blood count and routine liver and renal function tests. RESULTS: One patient responded to cyclosporine only. Thirteen of 32 patients (40%) had complete response, 12/32 patients (37%) had partial response leading to freedom from red cell transfusion, and 2/32 (7%) had no response. Five patients (16%) died due to thrombosis or hemorrhage within 3 months of therapy before their response to therapy could be assessed. The median period of review of the cases was 4 years and 6 months. CONCLUSION: Danazol is a useful addition to PNH therapy both in combination with cyclosporine for hypoplastic PNH and with prednisolone for other forms of PNH, and this therapy could be a good alternative where eculizumab and anti-lymphocyte globulin cannot be used for various reasons.
format Article
id doaj-e38cd860be5541708b2d8f6d7d0660ae
institution Directory of Open Access Journals
issn 1308-5263
language English
publishDate 2013-12-01
publisher Turkish Society of Hematology
record_format Article
spelling doaj-e38cd860be5541708b2d8f6d7d0660ae2025-11-03T00:27:55ZengTurkish Society of HematologyTurkish Journal of Hematology1308-52632013-12-0130436637010.4274/Tjh.2012.0199TJH-80664Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal HemoglobinuriaKanjaksha Ghosh0Manisha Madkaikar1Maya Gupta2Farah Jijina3National Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaNational Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaNational Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaNational Institute Of Immunohaematology, 13th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, India And Department Of Haematology, 10th Floor, Nms Building, Kem Hospital Campus, Parel, Mumbai, IndiaOBJECTIVE: The responses of 32 patients with paroxysmal nocturnal hemoglobinuria (PNH) were assessed after the patients were put on various combinations of danazol, prednisolone, and cyclosporine. METHODS: Nineteen males and 13 females aged between 14 and 60 years with confirmed diagnosis of PNH were treated with danazol (4), danazol + cyclosporine (7), cyclosporine (1), and prednisolone + danazol (20). Response to these interventions was assessed regularly. Danazol was added to cyclosporine in patients with aplastic bone marrow after 3 months of cyclocporine use only unless the former therapy was successful. Four patients with aplastic marrow received only danazol because they had renal insufficiency at presentation. Patients were evaluated with regular complete blood count and routine liver and renal function tests. RESULTS: One patient responded to cyclosporine only. Thirteen of 32 patients (40%) had complete response, 12/32 patients (37%) had partial response leading to freedom from red cell transfusion, and 2/32 (7%) had no response. Five patients (16%) died due to thrombosis or hemorrhage within 3 months of therapy before their response to therapy could be assessed. The median period of review of the cases was 4 years and 6 months. CONCLUSION: Danazol is a useful addition to PNH therapy both in combination with cyclosporine for hypoplastic PNH and with prednisolone for other forms of PNH, and this therapy could be a good alternative where eculizumab and anti-lymphocyte globulin cannot be used for various reasons.https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-80664cyclosporinedanazolhemoglobinuriaparoxysmalimmunosuppressionprednisolone
spellingShingle Kanjaksha Ghosh
Manisha Madkaikar
Maya Gupta
Farah Jijina
Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
cyclosporine
danazol
hemoglobinuria
paroxysmal
immunosuppression
prednisolone
title Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
title_full Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
title_fullStr Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
title_full_unstemmed Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
title_short Evaluation of Danazol, Cyclosporine, and Prednisolone as Single Agent or in Combination for Paroxysmal Nocturnal Hemoglobinuria
title_sort evaluation of danazol cyclosporine and prednisolone as single agent or in combination for paroxysmal nocturnal hemoglobinuria
topic cyclosporine
danazol
hemoglobinuria
paroxysmal
immunosuppression
prednisolone
url https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-80664
work_keys_str_mv AT kanjakshaghosh evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria
AT manishamadkaikar evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria
AT mayagupta evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria
AT farahjijina evaluationofdanazolcyclosporineandprednisoloneassingleagentorincombinationforparoxysmalnocturnalhemoglobinuria